Dr. Jeffrey Chamberlain's lab focuses on developing advanced gene therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder. The lab aims to improve the delivery and function of dystrophin proteins, utilizing innovative vector technologies. By designing new methods for gene replacement and editing, the research seeks to enhance the effectiveness and safety of treatments for DMD and related neuromuscular disorders.

Dr. Edwin R. Chapman's lab at the University of Wisconsin-Madison studies the molecular mechanics of membrane fusion in neurons, focusing on the release of neurotransmitters. The team utilizes innovative techniques to analyze the dynamics and structure of fusion pores, which are crucial for synaptic transmission. Their research aims to answer key questions about how neurons communicate and the potential implications for treating mental disorders.

Dr. Leigh Charvet's lab focuses on developing innovative treatments for cannabis addiction, particularly using a combination of transcranial direct current stimulation (tDCS) and mindfulness techniques. Their research aims to create an accessible home-based intervention that utilizes telehealth technology to help people recover from cannabis use disorder (CUD). By conducting clinical trials, the lab seeks to validate the efficacy of their approach and refine methods to ensure safety and effectiveness for participants.

Dr. Joseph Cheer’s lab focuses on understanding how the brain processes rewards and makes decisions based on memory and motivation. By studying the interaction between brain chemicals like acetylcholine and cannabinoids, the lab aims to uncover how these signals affect behaviors related to learning, memory, and reward-seeking activities. This research has important implications for treating memory disorders and motivational issues such as addiction.

Dr. Christine K. Fox's lab at the University of California, San Francisco focuses on understanding the complex link between childhood stroke, seizures, and the development of epilepsy. Her research aims to uncover the inflammatory processes and brain regions involved in these occurrences, using data from children who have experienced strokes. The ultimate goal is to improve recovery outcomes and find effective treatments for preventing epilepsy in young stroke patients.

Dr. Jeannie Chin's lab at Baylor College of Medicine focuses on understanding epilepsy, a serious neurological disorder. Their research investigates the role of a cellular pathway called mTOR, specifically its complex mTORC2, in the development of seizures. By combining techniques from genetics, molecular biology, and pharmacology, the team aims to uncover new mechanisms and therapies to better treat epilepsy and improve patient outcomes.

Dr. Hyunmi Choi's lab at Columbia University focuses on understanding how certain health risk factors relate to dementia and stroke in older adults with late-onset epilepsy. They investigate how vascular conditions, which affect blood vessels in the brain, may contribute to cognitive decline and increased stroke risk in these individuals. The lab aims to develop better strategies for assessing and reducing these risks to improve brain health in older adults.

Dr. Camillo Padoa-Schioppa's lab at Washington University focuses on understanding how the brain makes economic choices. By studying neuronal activity in the orbitofrontal cortex of monkeys, the lab investigates how decisions are influenced by various factors such as the number of available options and the internal state of the individual. This research is important for gaining insights into neurological disorders that disrupt economic choice behavior, like frontotemporal dementia and major depression.

Dr. Dandan Sun's lab at the University of Pittsburgh focuses on understanding the role of the choroid plexus in brain health, especially in relation to Alzheimer's disease and vascular dementia. The lab studies how the blood-cerebrospinal fluid (CSF) barrier can become dysfunctional, allowing harmful immune cells into the brain, which may contribute to cognitive decline. By investigating the mechanisms behind these changes, the lab aims to identify potential new therapies for treating these conditions.

Dr. Jeanne Bentley Lawrence's lab studies how an extra copy of chromosome 21 impacts cellular processes related to Down Syndrome and early-onset Alzheimer's disease. They focus on understanding the roles of non-coding RNAs and how they contribute to cell development and brain function. The lab employs innovative methods to investigate the molecular underpinnings of these conditions, aiming to inform therapeutic strategies that may be able to correct cognitive deficits associated with Down Syndrome.

Dr. Lauren Hablitz's research focuses on understanding how our body's sleep-wake cycle affects pain, particularly chronic neuropathic pain. Her lab investigates the glymphatic system, which helps remove waste from the brain, and how it interacts with the immune system. By studying these connections, the lab aims to discover new, non-drug therapies to manage chronic pain, thereby improving overall health and quality of life.

Dr. Theodore Price's research lab focuses on understanding the molecular mechanisms behind chronic pain using human tissue samples. By analyzing the first neurons in the pain pathway, they aim to develop new therapeutic targets for pain management. The lab uses innovative techniques like CRISPR screening to conduct functional genomic studies, connecting molecular findings to real human pain conditions.

Dr. H. Richard Koerber's lab focuses on understanding the mechanisms of chronic pain and the effects of neuromodulation therapies, particularly spinal cord and dorsal root ganglion stimulation. The lab investigates how different populations of spinal neurons process painful and non-painful stimuli, aiming to provide insights that could lead to better treatment options for chronic pain sufferers. They utilize advanced imaging and electrophysiological techniques to study neuronal activity before and after injury and the effectiveness of neuromodulatory devices.

Dr. Mark M. Churchland's lab at Columbia University focuses on understanding how the motor cortex in the brain contributes to voluntary movement. They study the complexity of neural activity in this region, which can vary significantly from one neuron to another, making it challenging to decipher how motor commands are generated. By utilizing advanced techniques like large-scale neural recordings and innovative experimental designs, the lab aims to develop insights that can help design interventions for movement disorders caused by brain damage.

Carla B. Green's lab focuses on understanding how the body's internal clocks regulate metabolism and contribute to health. They study a protein called Nocturnin, which plays a key role in processing certain molecules that influence metabolic functions. By examining specific gene functions in mice, they hope to uncover how disruptions in circadian rhythms can lead to obesity and other metabolic diseases, aiming to find potential treatments for related health issues.

Dr. Erik D Roberson's lab at the University of Alabama at Birmingham focuses on understanding how disruptions in circadian rhythms affect brain function in relation to Alzheimer's disease. They investigate how changes in neuronal excitability, particularly in certain inhibitory neurons, may contribute to the disease's early stages. Through innovative techniques, the lab aims to uncover mechanisms linking circadian biology with cognitive impairment and develop potential therapeutic strategies.

Dr. Steven A. Shea's lab focuses on understanding how our body's internal clocks, or circadian rhythms, affect heart health and risk for cardiovascular events. The research investigates how these rhythms influence how the heart responds to stress and daily activities, especially in those with conditions like high blood pressure or sleep apnea. By exploring these connections, the lab aims to improve the timing of therapies for cardiovascular diseases, potentially leading to better health outcomes.

Dr. Claire Clelland's lab at UCSF focuses on innovative approaches to address neurological diseases through advanced gene therapy techniques. They develop and test new methods to deliver treatments directly to the central nervous system (CNS) using ethically sourced human cadaver models. Additionally, their work involves utilizing CRISPR technology to target and edit genes associated with conditions like frontotemporal dementia, aiming to create effective therapeutic options for patients.

Dr. Eliseo A. Eugenin's lab at the University of Texas Medical Branch in Galveston focuses on understanding how HIV persists in the central nervous system (CNS) despite antiretroviral therapy. By studying cells like astrocytes and microglia, the lab aims to uncover mechanisms behind viral reservoirs and cellular damage that causes cognitive and motor impairments in individuals living with HIV. Their research seeks to identify new therapeutic strategies to eliminate these viral reservoirs and minimize damage to healthy brain cells.

Dr. Paul W. Czoty's research lab focuses on understanding cocaine use disorder (CUD) using nonhuman primate models. The lab investigates the role of nociceptin/orphanin FQ peptide (NOP) receptors in addiction and aims to develop new treatments for CUD using innovative pharmacotherapies. By combining behavioral studies and advanced imaging techniques, the lab seeks to provide insights into the neurobiology of addiction and improve treatment strategies for this public health issue.